How Much Does Semaglutide Cost Without Insurance? (2026 Pricing)

If you're looking into semaglutide for weight loss, the first thing most people Google after side effects is the price. The honest answer depends on which version you're taking, whether you have insurance, and how you're sourcing it. Brand-name Wegovy at full list price is over $1,400 a month. Compounded semaglutide through telehealth can be under $200. This guide walks through every realistic option and what you'd actually pay.

Quick price reference

Prices shift — Novo Nordisk adjusts list pricing; telehealth brands reprice frequently. These are representative as of early 2026.

Why there's such a huge gap

Semaglutide is the same active compound no matter the brand. The price gap between $1,400 Wegovy and $189 compounded semaglutide isn't about medication quality — it's about three other factors:

1. Patent and regulatory costs. Novo Nordisk spent over a decade and billions of dollars developing, testing, and getting FDA approval for semaglutide. Wegovy's price reflects the need to recoup those costs and fund research for the next drug. Compounded versions don't go through the same FDA approval process — they're prepared per-prescription by US-licensed compounding pharmacies under state pharmacy board oversight.

2. Manufacturing and supply. Brand-name Wegovy comes in prefilled injection pens, manufactured in sterile facilities, shipped through a national distribution network. Compounded semaglutide is prepared in smaller batches by compounding pharmacies, typically shipped in vials with syringes. The overhead is dramatically lower.

3. Insurance infrastructure. Brand-name drug pricing assumes most patients will be covered through insurance, where Novo Nordisk negotiates rebates with pharmacy benefit managers. The "list price" and the "net price insurance pays" are often very different — but if you're uninsured, you pay close to list. Compounded semaglutide through telehealth skips the insurance middle entirely.

Brand-name pricing, unpacked

Wegovy (semaglutide 2.4 mg, weight loss indication)

• List price: $1,402.98/month (as of 2026)
• With commercial insurance coverage: $0–$150/month depending on plan
• With a Novo Nordisk savings card (commercial insurance required): as low as $0/month for the first 2 years, capped benefit
• Without insurance: close to list price

Wegovy coverage for weight loss is still inconsistent. Most commercial plans exclude anti-obesity medications entirely, and Medicare is legally prohibited from covering them. This is the single most common reason patients move to compounded options.

Ozempic (semaglutide 0.5–2 mg, diabetes indication)

• List price: ~$1,030/month
• With Medicare Part D (if prescribed for diabetes): typically $35–$200/month
• With commercial insurance (for type 2 diabetes): often well-covered; coverage for off-label weight loss use is inconsistent
• Without insurance: close to list price

Some patients have a provider prescribe Ozempic off-label for weight loss, hoping for better coverage. This works sometimes — but many plans now require a diabetes diagnosis code for Ozempic coverage.

Rybelsus (oral semaglutide)

• List price: ~$990/month
• Lowest weight loss efficacy of the three (about 4–6% average vs 15% injectable)
• Usually only prescribed for diabetes, not weight loss

Compounded semaglutide pricing

Compounded versions are prepared by US-licensed compounding pharmacies when approved versions are in shortage or when a patient has a specific clinical need. The FDA's drug shortage list determines when compounding is legally permitted — semaglutide has been on and off the shortage list multiple times since 2022.

Typical compounded pricing through telehealth platforms:

Most platforms include the medication, provider visit, shipping, and ongoing messaging in the monthly fee. There is typically no separate pharmacy bill, no copay, no out-of-pocket cost surprise.

What insurance actually covers in 2026

This is the most confusing part of GLP-1 pricing. Here's the practical breakdown:

Medicare (65+)

Medicare Part D is prohibited by federal law from covering medications prescribed solely for weight loss. Wegovy and Zepbound are not covered for obesity. Ozempic and Mounjaro can be covered for type 2 diabetes.

There is an exception as of 2024: Medicare Part D plans can cover Wegovy if prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and obesity — but plans are not required to, and coverage is inconsistent.

Medicaid

Varies by state. Some Medicaid programs cover weight-loss GLP-1s (e.g., Virginia, North Carolina); many do not. Call your state Medicaid office to confirm before starting.

Commercial insurance (employer plans, individual marketplace)

• About 25–30% of commercial plans cover weight-loss GLP-1s in 2026, though coverage is expanding
• Most plans require prior authorization — proof of BMI 30+ (or 27+ with comorbidity), documented prior attempt at lifestyle intervention, and a prescription from a provider in your network
• Step therapy is common — plans may require you to try older, cheaper weight loss medications first
• Self-funded employer plans (most Fortune 500 employers) often specifically exclude weight-loss medications, even if the underlying carrier technically covers them

What to actually do

1. Call the number on the back of your insurance card
2. Ask: "Do you cover Wegovy or Zepbound for weight loss? What's my cost share, and what prior authorization is required?"
3. If covered: get the prior auth form, have your provider complete it, submit, expect a 1–2 week decision
4. If not covered: this is where compounded telehealth becomes the practical alternative

The real total cost of brand-name therapy

Even when brand-name Wegovy is covered, patients often pay meaningful out-of-pocket costs. A realistic annual budget:

Year 1 with commercial insurance covering Wegovy:

• Medication copay: $25–$150/month × 12 = $300–$1,800
• Provider visits: $0–$200 (varies by plan)
• Labs (baseline + annual): $100–$400
• Total: ~$400–$2,400

Year 1 without insurance (cash pay brand-name):

• Medication: $1,400/month × 12 = $16,800
• Provider visits (cash PCP): $150–$400
• Total: ~$17,000+

Year 1 compounded telehealth (Pallas):

• First month: $189
• Months 2–12: $299 × 11 = $3,289
• Total: $3,478 — all-inclusive

The gap between uninsured brand-name and compounded telehealth is roughly $13,000/year at current pricing. For most patients without coverage, compounded is the only economically viable option.

Hidden costs to watch for

When evaluating any option, make sure these are accounted for:

• Dose escalation — Wegovy, compounded, and Ozempic all titrate up over 4–5 months. Some pharmacies charge more at higher doses; others don't. Ask.
• Refill lags — if a pharmacy is delayed, you may pay out of pocket for a partial emergency fill elsewhere
• Prior auth denials — about 30% of initial Wegovy prior auth requests are denied. You can appeal, but plan for it
• Medication breaks — if you stop the medication, weight typically returns within 6–12 months per the STEP 4 extension data. Some patients end up paying for two rounds if they stop prematurely
• Lab work — some telehealth programs include baseline and follow-up labs; others don't. Cash lab work is $100–$300

Which option is right for your budget

Commercial insurance covers Wegovy: Use it. Even with copay, brand-name with full pharmacy support is generally the most reliable option.

Commercial insurance doesn't cover weight-loss GLP-1s, but covers Ozempic for diabetes: If you genuinely qualify for Ozempic (documented type 2 diabetes), this may be the cheapest path. Don't misrepresent your condition — insurance fraud is a real legal exposure and providers won't prescribe without documentation.

No insurance coverage for any GLP-1: Compounded telehealth is the practical option. At ~$3,500/year all-in, it's roughly 20% of the cost of cash-pay brand-name and covers the same active ingredient.

Medicare, no cardiovascular indication: Compounded telehealth. Medicare Part D won't cover Wegovy, and paying cash for brand-name at retirement budgets is rarely realistic.

Looking to switch from brand-name to compounded: Talk to your provider about continuity. Most telehealth platforms can match your current dose and continue therapy seamlessly. Read our guide on compounded vs brand-name GLP-1 for the clinical differences.

Frequently asked questions

Is there a generic version of semaglutide? Not yet. Semaglutide is under patent in the US until 2031 (brand-name) or 2033 (various formulation patents). Compounded semaglutide is legally distinct from a generic — it's prepared per-prescription by compounding pharmacies rather than manufactured as an FDA-approved generic drug.

Can I use HSA or FSA funds for semaglutide? Yes, typically. Semaglutide prescribed by a licensed provider is an eligible medical expense for HSA and FSA accounts. Most telehealth platforms provide receipts suitable for reimbursement. Check with your plan administrator to confirm specific rules.

What happens if the FDA declares semaglutide no longer in shortage? When a drug is removed from the FDA shortage list, compounding pharmacies may have 60–90 days to continue existing prescriptions but generally cannot accept new patients for that compound. This happened temporarily to tirzepatide in October 2024, though it was later re-added to the shortage list. Compounded GLP-1 availability can change on relatively short notice.

Why is Wegovy more expensive than Ozempic if they're the same drug? Same active ingredient (semaglutide) but different dose ceilings and different labeled indications. Wegovy goes up to 2.4 mg/week; Ozempic goes up to 2.0 mg/week. Wegovy is FDA-approved for weight loss, Ozempic is approved for type 2 diabetes. Insurance companies price these indications differently.

Does Pallas require insurance? No. Pallas plans are cash-pay only — no insurance processing. This is what lets us keep the flat $189/$299 pricing. Patients can separately submit receipts to HSA/FSA accounts, but we don't coordinate with insurance carriers directly.

Will compounded pricing stay this low? Unclear. If the FDA removes semaglutide from the shortage list permanently, compounding availability drops and prices may rise. If Novo Nordisk lowers Wegovy's list price significantly (which they've signaled interest in doing), the gap narrows. For now, the cost difference is dramatic.

---

Bottom line: If insurance covers Wegovy, use it. If not, compounded telehealth is 20% of the cash-pay brand-name cost and covers the same active ingredient. Pallas plans are $189 first month, $299/mo after, all-inclusive — roughly $3,500/year total vs $17,000 for uninsured brand-name.